HEALTHSTAT NEWS
STAT+: 931 days. The drug approval scandal hiding in plain sight
Northwest Biotherapeutics submitted a marketing application for its brain cancer treatment DCVax to U.K. regulators in late December 2023 under an expedited pathway expecting a 150-day review. Over 931 days later, the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has not approved the drug and refuses to comment, deferring updates to the company.
Mentioned
Related Signal
Adjacent reporting
- STAT+: Following dispute with FDA, UniQure is cleared to submit Huntington’s treatment for approval
- STAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more
- STAT+: FDA approves Sanofi diabetes drug for children with stage 3 diabetes
- STAT+: FDA to reconsider treatment for rare cancer after its surprise rejection
- White House bats down speculation that Trump got access to Eli Lilly obesity drug for ‘compassionate use’
- STAT+: FDA to reconsider treatment for rare cancer after surprise rejection